1. Home
  2. MMA vs CALC Comparison

MMA vs CALC Comparison

Compare MMA & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alta Global Group Limited

MMA

Alta Global Group Limited

HOLD

Current Price

$0.39

Market Cap

13.9M

Sector

N/A

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$0.75

Market Cap

11.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MMA
CALC
Founded
2013
2011
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.9M
11.2M
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
MMA
CALC
Price
$0.39
$0.75
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
81.6K
285.9K
Earning Date
05-20-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.30
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$3.33
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$0.46
52 Week High
$2.00
$7.20

Technical Indicators

Market Signals
Indicator
MMA
CALC
Relative Strength Index (RSI) 33.44 47.84
Support Level $0.35 $0.52
Resistance Level $0.50 $0.77
Average True Range (ATR) 0.03 0.09
MACD -0.01 0.01
Stochastic Oscillator 0.09 30.50

Price Performance

Historical Comparison
MMA
CALC

About MMA Alta Global Group Limited

MMA Inc develops technology solutions for the martial arts and combat sports sector. Its platform is designed to support gyms and related businesses by improving areas such as sales channels, customer onboarding, and member engagement. The platform also connects participants, gyms, and communities within the sector, enabling digital management and interaction.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: